Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis

Journal of Autoimmunity

Volumn 52, Issue , 2014, Pages 64-73

  Thiruppathi, Muthusamy ^a   Sheng, Jian Rong ^a   Li, Liangcheng ^a   Prabhakar, Bellur S ^a   Meriggioli, Matthew N ^b  

^a UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

EAMG; Fc; IgG; IVIg; Multimers; Regulatory T cells

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; CD40 ANTIGEN; FC RECEPTOR IIB; GAMMA INTERFERON; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; M 045; NICOTINIC RECEPTOR; POLYMER; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; AUTOANTIBODY; CHOLINERGIC RECEPTOR; IMMUNOGLOBULIN; RECOMBINANT PROTEIN; IMMUNOLOGIC AGENT; RECOMBINANT POLYVALENT IMMUNOGLOBULIN G2A FC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL COUNT; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DOWN REGULATION; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; T LYMPHOCYTE; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; PROCEDURES; DRUG EFFICACY; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOANTIBODIES; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY;

EID: 84904320258     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.12.014     Document Type: Article

References (72)

1. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. JClin Invest 2006, 116:2843-2854.
2. Meriggioli M.N., Sanders D.B. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009, 8:475-490.
3. Zinman L., Ng E., Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007, 68:837-841.
4. Bertorini T.E., Nance A.M., Horner L.H., Greene W., Gelfand M.S., Jaster J.H. Complications of intravenous gamma globulin in neuromuscular and other diseases. Muscle Nerve 1996, 19:388-391.
5. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through inhibition of Fc receptor. Science 2001, 291:484-486.
6. Nimmerjahn F., Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. JExp Med 2007, 204:11-15.
7. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
8. Morgan E.L., Tempelis C.H. The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression. JImmunol 1978, 120:1669-1671.
9. Siragam V., Brinc D., Crow A.R., Song S., Freedman J., Lazarus A.H. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?. JClin Invest 2005, 115:155-160.
10. Bazin R., Lemieux R., Tremblay T., St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent invitro and invivo phagocytosis of blood cells. Br J Haematol 2004, 127:90-96.
11. Teeling J.L., Jansen-Hendriks T., Kuijpers T.W., de Haas M., van de Winkel J.G., Hack C.E., et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001, 98:1095-1099.
12. Strohl W.R., Knight D.M. Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 2009, 20:668-672.
13. Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODYTM technology. Curr Opin Biotechnol 2009, 20:692-699.
14. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7:715-725.
15. Vaccaro C., Bawdon R., Wanjie S., Ober R.J., Ward E.S. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A 2006, 103:18709-18714.
16. Nimmerjahn F., Ravetch J.V. Fc-receptors as regulators of immune responses. Nat Rev Immunol 2008, 8:34-47.
17. Czajkowsky D.M., Hu J., Shao Z., Pleass R.J. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012, 4:1015-1028.
18. Clark M.R. IgG effector mechanisms. Chem Immunol 1997, 65:88-110.
19. Taylor L., Bachler M., Duncan I., Keen S., Fallon R., Mair C., et al. Invitro and invivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions. JLeukoc Biol 2002, 72:522-529.
20. Scott M.G., Briles D.E., Nahm M.H. Selective IgG subclass expression: biologic, clinical and functional aspects. The human IgG subclasses: molecular analysis of structure and function 1990, 161-183. Pergamon Press, Oxford. F. Shakib (Ed.).
21. Hussain R., Dawood G., Abrar N., Toossi Z., Minai A., Dojki M., et al. Selective increases in antibody isotypes and immunoglobulin G subclass responses to secreted antigens in tuberculosis patients and healthy household contacts of the patients. Clin Diagn Lab Immunol 1995, 2:726-732.
22. Negi V.S., Elluru S., Sibéril S., Graff-Dubois S., Mouthon L., Kazatchkine M.D., et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. JClin Immunol 2007, 27:233-245.
23. Tha- T., Bayry J., Metselaar H.J., Kaveri S.V., Kwekkeboom J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008, 29:608-615.
24. Cholette J.M., Lerner N.B. Use of blood products. Pediatric critical care study guide text and review 2012, 427-450. Springer-Verlag, London. S.E. Lucking, F.A. Maffei, R.F. Tamburro, N.J. Thomas (Eds.).
25. Jain A., Olsen H.S., Vyzasatya R., Burch E., Sakoda Y., Mérigeon E.Y., et al. Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice. Arthritis Res Ther 2012, 14:R192.
26. Bellone M., Ostlie N., Lei S., Conti-Tronconi B.M. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the α subunits of Torpedo californica and murine acetylcholine receptors. Eur J Immunol 1991, 21:2303-2310.
27. Sheng J.R., Li L., Ganesh B.B., Vasu C., Prabhakar B.S., Meriggioli M.N. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. JImmunol 2006, 177:5296-5306.
28. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr Protoc Immunol 2001, Chapter 15: Unit 15.8, 4-9.
29. Lindstrom J., Einarson B., Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol 1981, 74(Pt C):432-460.
30. Jolles S., Sewell W.A., Misbah S.A. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005, 142:1-11.
31. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIg anti-inflammatory activity with recombinant IgG Fc. Science 2008, 320:373-376.
32. Augener W., Friedman B., Brittinger B. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)?. Blut 1985, 50:249-252.
33. Zhu K.Y., Feferman T., Maiti P.K., Souroujon M.C., Fuchs S. Intravenous immunoglobulin suppresses experimental myasthenia gravis: immunological mechanisms. JNeuroimmunol 2006, 176:187-197.
34. Niknami M., Wang M.X., Nguyen T., Pollard J.D. Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis). JPeripher Nerv Syst 2013, 18:141-152.
35. Basta M., Fries L.F., Frank M.M. High doses of intravenous Ig inhibit invitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991, 77:376-380.
36. Lutz H.U., Stammler P., Jelezarova E., Nater M., Späth P.J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996, 88:184-193.
37. Boros P., Gondolesi G., Bromberg J.S. High dose intravenous immunoglobulin treatment: mechanisms of action. Liver Transpl 2005, 11:1469-1480.
38. Berrih-Aknin S., Ragheb S., Le Panse R., Lisak R.P. Ectopic germinal centers, BAFF, and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev 2013, 12:885-893.
39. Lee B.O., Moyron-Quiroz J., Rangel-Moreno J., Kusser K.L., Hartson L., Sprague F., et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. JImmunol 2003, 171:5707-5717.
40. Sakurai D., Kanno Y., Hase H., Kojima H., Okumura K., Kobata T. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol 2007, 37:110-118.
41. Venkatesh J, Kawabata D, Kim S, Xu X, Chinnasamy P, Paul E, etal. Selective regulation of autoreactive B cells by FcgammaRIIB. J Autoimmun;32:149-157.
42. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010, 10:328-343.
43. Conti-Fine B.M., Milani M., Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann NY Acad Sci 2008, 1132:193-209.
44. Engel P., Gómez-Puerta J.A., Ramos-Casals M., Lozano F., Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011, 63:127-156.
45. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
46. Cheatem D., Ganesh B.B., Gangi E., Vasu C., Prabhakar B.S. Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4+CD25+ regulatory T cell function. Clin Immunol 2009, 131:260-270.
47. Ganesh B.B., Cheatem D.M., Sheng J.R., Vasu C., Prabhakar B.S. GM-CSF-induced CD11c+CD8a-dendritic cells facilitate Foxp3+ and IL-10+ regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol 2009, 21:269-282.
48. Dieckmann D., Bruett C.H., Ploettner H., Lutz M.B., Schuler G. Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. JExp Med 2002, 196:247-253.
49. Zheng S.G., Wang J.H., Gray J.D., Soucier H., Horwitz D.A. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. JImmunol 2004, 172:5213-5221.
50. Veldman C., Nagel A., Hertl M. Type I regulatory T cells in autoimmunity andinflammatory diseases. Int Arch Allergy Immunol 2006, 140:174-183.
51. Nagane Y., Utsugisawa K., Obara D., Yamagata M., Tohgi H. Dendritic cells in hyperplastic thymuses from patients with myasthenia gravis. Muscle Nerve 2003, 27:582-589.
52. Xiao B.G., Duan R.S., Link H., Huang Y.M. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor- pulsed dendritic cells. Cell Immunol 2003, 223:63-69.
53. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. JImmunol 2005, 174:1729-1737.
54. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. JExp Med 1996, 184:747-752.
55. + T-helper and a T-killer cell. Nature 1998, 393:474-478.
56. Sayegh M.H., Turka L.A. Tcell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. JAm Soc Nephrol 1995, 6:1143-1150.
57. Mahnke K., Johnson T.S., Ring S., Enk A.H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. JDermatol Sci 2007, 46:159-167.
58. Boruchov A.M., Heller G., Veri M.C., Bonvini E., Ravetch J.V., Young J.W. Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. JClin Invest 2005, 115:2914-2923.
59. Dhodapkar K.M., Kaufman J.L., Ehlers M., Banerjee D.K., Bonvini E., Koenig S., et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc Natl Acad Sci U S A 2005, 102:2910-2915.
60. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Théry C., Rescigno M., et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. JExp Med 1999, 189:371-380.
61. Nicholson L.B., Kuchroo V.K. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr Opin Immunol 1996, 8:837-842.
62. Baggi F., Andreetta F., Caspani E., Milani M., Longhi R., Mantegazza R., et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. JClin Invest 1999, 104:1287-1295.
63. Balasa B., Deng C., Lee J., Bradley L.M., Dalton D.K., Christadoss P., et al. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. JExp Med 1997, 186:385-391.
64. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
65. Gomez A.M., Van Den Broeck J., Vrolix K., Janssen S.P., Lemmens M.A., Van Der Esch E., et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43:353-370.
66. Zhang G.X., Navikas V., Link H. Cytokines and the pathogenesis of myasthenia gravis. Muscle Nerve 1997, 20:543-551.
67. Shi F.D., Li H., Wang H., Bai X., van der Meide P.H., Link H., et al. Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. JImmunol 1999, 162:5757-5763.
68. Rutella S., Danese S., Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108:1435-1440.
69. Belkaid Y., Oldenhove G. Tuning microenvironments: Induction of regulatory T cells by dendritic cells. Immunity 2008, 29:362-371.
70. Karsten C.M., Köhl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune diseases. Immunobiology 2012, 217:1067-1079.
71. Liu Y., Gao X., Masuda E., Redecha P.B., Blank M.C., Pricop L. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. JImmunol 2006, 177:8440-8447.
72. Mekhaiel D.N., Czajkowsky D.M., Andersen J.T., Shi J., El-Faham M., Doenhoff M., et al. Polymeric human Fc-fusion proteins with modified effector functions. Sci Rep 2011, 1:124.